Search research articles
Contact Us
Filters
Showing results (21-30 of 102) with videos related to
Page
of 11
Sort By:
BMC Cancer
|
April 26, 2023
Correction: Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States
Lisa M Hess, Yimei Han, Yajun Emily Zhu, et al.
Advances in Hematology
|
January 9, 2023
Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study
Lisa M Hess, Yongmei Chen, Paolo B Abada, et al.
JCO Precision Oncology
|
June 23, 2022
Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers in the United States
Debora S Bruno, Lisa M Hess, Xiaohong Li, et al.
Journal of Medical Economics
|
December 1, 2022
Costs of biomarker testing among patients with metastatic lung or thyroid cancer in the USA: a real-world commercial claims database study
Lisa M Hess, Diane Michael, Peter M Krein, et al.
Thyroid Research
|
February 13, 2022
Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced/metastatic medullary thyroid cancer
Rohan Parikh, Lisa M Hess, Elizabeth Esterberg, et al.
Cancer
|
July 29, 2010
Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis
Lisa M Hess, Nan Rong, Patrick O Monahan, et al.
Perspectives in Health Information Management
|
April 26, 2019
Challenges of Using ICD-9-CM and ICD-10-CM Codes for Soft-Tissue Sarcoma in Databases for Health Services Research
Lisa M Hess, Yajun E Zhu, Tomoko Sugihara, et al.
Immunotherapy
|
June 18, 2021
Efficacy of immune checkpoint inhibitor therapy in patients with <i>RET</i> fusion-positive non-small-cell lung cancer
Naleen Raj Bhandari, Lisa M Hess, Yimei Han, et al.
Journal of the National Cancer Institute
|
January 2, 2014
Re: Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer
Lisa M Hess, Gebra Carter, Lee Smolen, et al.
The Patient
|
July 31, 2014
Preference elicitation tool for abnormal uterine bleeding treatment: a randomized controlled trial
Lisa M Hess, Abigail Litwiller, John Byron, et al.
Page
of 11
Search research articles
Search
Showing results (21-30 of 102) with videos related to
Sort By:
Page
of 11
BMC Cancer
|
April 26, 2023
Correction: Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States
Lisa M Hess, Yimei Han, Yajun Emily Zhu, et al.
Advances in Hematology
|
January 9, 2023
Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study
Lisa M Hess, Yongmei Chen, Paolo B Abada, et al.
JCO Precision Oncology
|
June 23, 2022
Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers in the United States
Debora S Bruno, Lisa M Hess, Xiaohong Li, et al.
Journal of Medical Economics
|
December 1, 2022
Costs of biomarker testing among patients with metastatic lung or thyroid cancer in the USA: a real-world commercial claims database study
Lisa M Hess, Diane Michael, Peter M Krein, et al.
Thyroid Research
|
February 13, 2022
Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced/metastatic medullary thyroid cancer
Rohan Parikh, Lisa M Hess, Elizabeth Esterberg, et al.
Cancer
|
July 29, 2010
Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis
Lisa M Hess, Nan Rong, Patrick O Monahan, et al.
Perspectives in Health Information Management
|
April 26, 2019
Challenges of Using ICD-9-CM and ICD-10-CM Codes for Soft-Tissue Sarcoma in Databases for Health Services Research
Lisa M Hess, Yajun E Zhu, Tomoko Sugihara, et al.
Immunotherapy
|
June 18, 2021
Efficacy of immune checkpoint inhibitor therapy in patients with <i>RET</i> fusion-positive non-small-cell lung cancer
Naleen Raj Bhandari, Lisa M Hess, Yimei Han, et al.
Journal of the National Cancer Institute
|
January 2, 2014
Re: Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer
Lisa M Hess, Gebra Carter, Lee Smolen, et al.
The Patient
|
July 31, 2014
Preference elicitation tool for abnormal uterine bleeding treatment: a randomized controlled trial
Lisa M Hess, Abigail Litwiller, John Byron, et al.
Page
of 11